

Opening Remarks

Michael A. Mussallem
Chairman and CEO



Edwards

Our Credo

A photograph of a male doctor in a blue and white checkered shirt using a stethoscope to examine a young child. The child is smiling and looking up. The background is slightly blurred, showing other people and a fence.

At Edwards Lifesciences, we are dedicated to providing innovative solutions for people fighting cardiovascular disease.

**Through our actions,
we will become trusted
partners with customers,
colleagues, and patients—**

creating a community unified in its mission to improve the quality of life around the world. Our results will benefit customers, patients, employees and shareholders.

We will celebrate our successes, thrive on discovery, and continually expand our boundaries. We will act boldly, decisively, and with determination on behalf of people fighting cardiovascular disease.

Helping patients is our life's work, and

life is now

Our Aspirations

Edwards is a global leader dedicated to...

Transforming patient lives
with **breakthrough**
medical technologies

Excelling as a **trusted partner**
through distinguished quality and
integrity



Delivering exceptional
shareholder value

Passionate engagement that
strengthens our communities

Fostering an **inclusive culture** where all
employees grow and thrive

Edwards Lifesciences at a Glance



600K+

Patients Treated with
Transcatheter Therapies

15,000+

Global Employees



50%+

Millennials and Generation Z



~2,000

Engineers



Investment in R&D

17-18%

of 2021E sales



80%+

Charitable employee
engagement



7

Manufacturing Facilities
Around the World



Resilient Supply
Chain

95%+

Sales from Products with
#1 Global Market Share

Patient-Focused Innovation Strategy



Innovation

Pioneer breakthrough technologies with compelling evidence

Leadership

Lead groundbreaking standards of care through trusted relationships

Focus

Singular focus on the large unmet needs of structural heart and critically ill patients

Create Meaningful Value by Transforming Patient Care

Edwards' patient-focused innovation strategy has produced sustained underlying sales growth



Focused on opportunities where **patient demand** is very large




Track record of **triple wins:**

- Improved outcomes
- Enhanced quality of life
- Cost effectiveness



Long-term investments have yielded high-value, organic growth

Edwards Sales
(\$ in billions)



Conference Highlights



Delivering results in **2021**
while investing to create
future value

2022 expected to be a
year of significant
milestone achievements

Long-term **global
market opportunity** is
expanding

Highly **strategic**
and experienced
leadership team

2021 Delivering Results to Drive Value

Strengthening Positions Despite COVID

- TAVR therapy and geographic expansion
- Critical Care exceeding growth expectations
- Surgical driving adoption of premium technologies
- TMTT implementing bold agenda

Achieving Clinical and R&D Milestones

- Gaining patient experience in multiple breakthrough therapies
- Advancing portfolio of catheter-based solutions
- R&D 17-18% of 2021E sales

Delivering Results while Investing to Create Future Value

- Strong earnings growth while aggressively investing in R&D and infrastructure
- Resilient global supply chain

Estimated 2021
Sales Growth:
High-Teens

Estimated Adjusted
EPS growth:
21-23%

**October Guidance
Unchanged**

2022 expected to be a year of significant milestone achievements and investment in our future



TAVR

Moderate AS trial enrollment
SAPIEN X4 trial enrollment



TMTT

PASCAL - DMR approval in the U.S.
EVOQUE TR approval in Europe



SURGICAL

MITRIS approval in the U.S.
Continued adoption of RESILIA



CRITICAL CARE

HemoSphere with Viewfinder
Smart BP enrollment

Low double-digits
Underlying sales growth

2022
EXPECTATIONS

\$2.50 - \$2.65
Adjusted EPS

Global Market Opportunity by 2028

Currently around \$10 billion




TAVR

TMTT

Surgical

Critical Care



**Nearly
\$20B**

We are just getting started

2021 Investor Conference Agenda



Transcatheter Aortic Valve Replacement

Larry Wood

Surgical Structural Heart

Daveen Chopra

Transcatheter Mitral and Tricuspid Therapies

Bernard Zovighian

Critical Care

Katie Szyman

Financial Outlook


Scott Ullem

Closing Remarks

Mike Mussallem

Q&A Session

Edwards' Executive Leadership Team



Mike Mussallem
Chairman & CEO



Daveen Chopra
Surgical Structural Heart



Christine McCauley
Human Resources



Gary Sorsher
Quality, Regulatory, Clinical



Huimin Wang, M.D.
Japan, Asia and Pacific



Don Bobo, Jr.
Strategy & Corporate Development



Dirksen Lehman
Public Affairs



Joe Nuzzolese
Global Supply Chain



Katie Szyman
Critical Care



Larry Wood
Transcatheter Aortic Valve Replacement



Todd Brinton, M.D.
Chief Scientific Officer



Jean-Luc Lemerrier
EMEA, Canada and Latin America



Arnold Pinkston
General Counsel



Scott Ullem
Chief Financial Officer



Bernard Zovighian
Transcatheter Mitral & Tricuspid Therapies

Long-tenured expert
healthcare executives

Highly strategic and
collaborative team

Incentives aligned with
shareholders



Edwards

Helping Patients is Our Life's Work, and
life is now